UroGen Pharma Ltd (NAS:URGN)
$ 13.05 -0.76 (-5.5%) Market Cap: 549.59 Mil Enterprise Value: 437.91 Mil PE Ratio: 0 PB Ratio: 18.74 GF Score: 72/100

Q2 2021 Urogen Pharma Ltd Earnings Call Transcript

Aug 04, 2021 / 12:30PM GMT
Release Date Price: $15.3 (-2.61%)
Operator

Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma's Second Quarter 2021 Financial Results and Business Update Conference Call.

It is now my pleasure to turn the call over to Sara Sherman, Head of Investor Relations for UroGen Pharma. Please go ahead.

Sara Sherman

Thank you, Operator, and welcome everyone to UroGen Pharma's second quarter 2021 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended June 30, 2021. The press release can be accessed on the Investors portion of our website at investors.urogen.com.

Joining me on the call today are Liz Barrett, President and Chief Executive Officer; Jeff Bova, Chief Commercial Officer; Dr. Mark Schoenberg, Chief Medical Officer; and Molly Henderson, Chief Financial Officer.

Please note that we continue to conduct our calls from different locations. So we appreciate your patience and understanding

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot